Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TAK-881 by Takeda Pharmaceutical for Primary Immune Deficiency (PID): Likelihood of Approval
TAK-881 is under clinical development by Takeda Pharmaceutical and currently in Phase III for Primary Immune Deficiency (PID). According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical's TAK-881?
TAK-881 is an antibody, blood derivative and recombinant enzyme commercialized by Takeda Pharmaceutical, with a leading Phase III program in...